ÄÐÈ˹¬µî

Careers Contact Locations

ÄÐÈ˹¬µî.

  • ÄÐÈ˹¬µî
  • Who We Are
    • Our Vision
    • Our History
    • Our Leadership
  • What We Do
    • Overview
    • Our Products
    • Our Solutions
    • Our Technology
    • Our Research
    • Our Diagnostics
  • News & Media
    • Press Releases
    • Announcements
    • Events
    • Presentations
  • Investors
    • Overview
    • News / Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Careers
  • Contact
  • Locations

Press Releases

News & Media

News & Media

  • Press Releases
  • Announcements
  • Events
  • Presentations

ÄÐÈ˹¬µî to Present at the 39th Annual J.P. Morgan Healthcare Conference

Jan 5, 2021

US FDA Accepts Regulatory Submission from Pfizer and OPKO for Review of Somatrogon to Treat Pediatric Patients with Growth Hormone Deficiency

Jan 4, 2021

ÄÐÈ˹¬µî's BioReference Laboratories Reports Results of the Largest COVID-19 Public School Testing Program Nationwide

Jan 4, 2021

Buffalo Bills and ÄÐÈ˹¬µî's BioReference Laboratories Initiate the First Large Scale, Mandatory COVID-19 Fan Testing Program

Dec 31, 2020

ÄÐÈ˹¬µî Appoints Dr. Roger Medel to its Board of Directors

Dec 21, 2020

ÄÐÈ˹¬µî to Participate in Three Upcoming Investment Conferences

Nov 11, 2020

ÄÐÈ˹¬µî Reports 2020 Third Quarter Business Highlights and Financial Results

Oct 29, 2020

ÄÐÈ˹¬µî's BioReference Laboratories Launches Multiplex COVID-19 and Influenza A/B Test

Oct 20, 2020

ÄÐÈ˹¬µî to Report Third Quarter 2020 Financial Results on October 29, 2020

Oct 13, 2020

ÄÐÈ˹¬µî's BioReference Laboratories Launches COVID-19 Testing Program for New York City Schools

Oct 9, 2020
RSS
  • Prev
    • 1...
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • 12
    • ...49
    Next

    OPKO HEALTH, INC.
    4400 Biscayne Boulevard
    Miami, FL 33137

    305-575-4100
    contact@opko.com

    © 2023 ÄÐÈ˹¬µî. All Rights Reserved.
    Privacy Policy Governance Terms of Use Sitemap